

REVIEW ARTICLE

ATROPINE AND ATROPINE-LIKE SUBSTANCES USABLE IN WARFARE

Jiri Patocka^{1,2} ✉, Romana Jelinkova³

¹ Institute of Radiology, Toxicology and Civil Protection, Faculty of Health and Social Studies, University of South Bohemia České Budějovice, České Budějovice, Czech Republic

² Biomedical Research Centre, University Hospital, Hradec Kralove, Czech Republic

³ NBC Defence Institute, University of Defence, Vyškov, Czech Republic

Received 29th March 2017.

Revised 2nd May 2017.

Published 9th June 2017.

Summary

Plant tropane alkaloids atropine and scopolamine are very strong anticholinergic drugs used in medicine and also found their place in military medicine, in particular atropine as an antidote in case of poisonings by nerve gases. Atropine and scopolamine both easily penetrate the blood-brain barrier and may cause central nervous system toxicity. Its symptoms are delirium, restlessness, confusion, and impairment of mental capacities. Scopolamine is much more likely to produce sedation and amnesia than atropine. Synthetic atropine-like compounds are also strong anticholinergics, and found use as a modern type of chemical weapons that incapacitate enemy for some time, but do not kill him. They are so-called non-lethal weapons, which are able to temporarily disable personnel from combat action and to protect the environment without limiting desired negative consequences to the enemy's national economy. Such non-lethal weapons is Agent BZ.

Key words: Tropane alkaloids; atropine; scopolamine; Agent BZ; non-lethal weapons

INTRODUCTION

Atropine (hyoscyamine) is plant alkaloid and together with scopolamine they are the predominant anticholinergic tropane alkaloids in the *Datura* genus, occurring in all plant organs. Atropine and related tropane alkaloids are widespread in the plant kingdom and their medicinal and recreational properties have been well known to many cultures for many centuries (Brighetti, 1966). Plants in the genus *Datura* (family *Solanaceae*), which produce the tropane alkaloids, have well deserved sinister reputations for being poisonous (Le Strange, 1977). Among the most important plants which produce tropane alkaloids, these are especially *Atropa belladonna* (Deadly nightshade), *Datura stramonium* (Jimson weed or thorn apple), *Hyoscyamus niger* (henbane), and *Mandragora officinarum* (common mandrake).

BOTANICS AND ETHNOBOTANICS OF THE TROPANE ALKALOIDS PRODUCING PLANTS OF THE FAMILY *SOLANACEAE*

Plants which produce tropane alkaloids are native to Europe, North Africa, and Western Asia. Its distribution extends from Great Britain in the west to western Ukraine and Iran in the east. It is also naturalised and/or

✉ University of South Bohemia České Budějovice, Faculty of Health and Social Studies, Institute of Radiology, Toxicology and Civil Protection, Jírovčova 24/1347, 370 04 České Budějovice, Czech Republic
toxicology@toxicology.cz

introduced in some parts of Canada and the United States. These have a long history of use as medicine, cosmetic, and poison (Buess, 1952). All grow like weeds in nature and are easily accessible.

***Atropa belladonna* (Deadly Nightshade)**

Atropa belladonna, commonly known as deadly nightshade, is a perennial plant in the *Solanaceae* family whose leaves and berries are extremely toxic. The name *Atropa* comes from one of the three Fates of Greek mythology: Lachesis measured the thread of destiny at birth, Clotho spun it, controlling destiny and Atropos cut the thread of life, bringing death. This plant containing toxic tropane alkaloids such as atropine and scopolamine. These toxins cause hallucinations and delirium, which is why it has long been used as poison, however belladonna has been used medicinally since ancient times as a muscle relaxant and is also used to regulate the heart and pain (Ramoutsaki et al., 2002).

Deadly nightshade is an herbaceous perennial. It grows to a height of 1.5 m and has branched stem with oval shaped, pointed leaves on alternate sides. In the early summer it produces brownish, tubular flowers, which, over ensuing months, turn into hard green fruit that then ripens to dark purple and shiny black (Fig. 1). All parts of the plant are poisonous and are a potent source of atropine (Ylinen et al., 1986).



Figure 1. Flowering shrub of deadly nightshade (*Atropa belladonna*). Photo © Romana Jelinkova.

The plant was well known to the Ancient Greeks and it is a strong candidate for the potion that the sorceress Circe administered to the sailors on Odysseus' ship. This subsequently drove them mad and 'turned them into swine'. Odysseus resisted the poison by taking the antidote 'moli' which was probably either the snowdrop (*Galanthus nivalis*) or the snowflake (*Leucojum vernum*) (Lee, 1999). The deadly nightshade was also an important plant in the witches' pharmacopoeia and it was regarded as one of the Devil's favourite plants. Nightshade was a constituent of their flying ointments (sorcerers pomade). This was rubbed into the skin and genitals and the witch

would then experience delusions, hallucinations and sometimes sensations of levitation or flying. Sexual arousal could also ensue together with orgasm (Lee, 2007).

***Datura stramonium* (Jimson Weed, Devil's snare, Thorn Apple)**

Datura stramonium is an extremely poisonous plant of the nightshade family (Urich et al., 1982). Currently growing everywhere from the tropics to the temperate zone. This plant is native to Central America but is found as a naturalised weed in entire Europe. In the Czech Republic it grows scattered from the lowlands to the foothills. It is a foul-smelling, erect, freely branching herb that forms a bush up to 60 to 150 cm tall. The leaves are pointed at the edges and yellowish at the base. The flowers are white trumpets, 10-cm long, and the fruits are green, spiny ovals, hence the name 'thorn apple'. These split to reveal numerous black seeds. Tropane alkaloids are concentrated in the seeds although all parts of the plant are poisonous (Friedman and Levin, 1989; Gaie et al., 2013). The name Jimson weed commemorates the event when settlers arrived to Jamestown Island, Virginia in 1607 and found the island overrun by this weed. Many of them ate the plant and died after experiencing delusions, convulsions and respiratory failure (Fowler, 2015).

Datura stramonium is attributed with both poisonous and medicinal values. It contains varieties of toxic tropane alkaloids such as atropine, hyoscamine, and scopolamine (Abdelouahab et al., 2011). In Ayurveda, it has been used for curing various ailments including wounds, inflammation, rheumatism, sciatica, swellings, fever, and asthma. A wide range of medicinal values has been attributed to this plant. Different studies reported safety and toxicity aspects while other studies reported analgesic, anti-inflammatory, anti-viral, anti-diarrheal, etc. activities of different extracts of the plant (Parveen et al., 2016).

***Hyoscyamus Niger* (Henbane)**

Hyoscyamus niger is an annual or biennial that grows to 75 cm and has a thick stem and toothed leaves. The plant is hairy and sticky and has an unpleasant smell. It produces flowers near the top of stems that are yellow with purple veins. The fruit hardens into spines and remains on the plant throughout winter. The whole plant is highly poisonous, containing a mixture of tropane alkaloids (Aparna et al., 2015).

Hyoscyamus niger is one of the drugs of Ayurvedic materia medica known as Parasika Yavani, which is mainly used for respiratory disorders. It is used in Ayurvedic system of medicine for treating insomnia, psychiatric disorders, epilepsy, swelling, pain, and breathlessness. Some of the chief constituents found in the drug are hyoscyamine, apoatropine, hyoscyne, skimmianine, scopolamine, and belladonines. Various experiments proved antihistaminic, antipyretic, antimicrobial, antispasmodic, analgesic, anti-inflammatory, antiallergic and sedative property of the drug (Begum et al., 2010; Aparna et al., 2015).

***Mandragora officinarum* (Mandrake, Common Mandrake, Devil's Apples, Love Apple)**

Mandragora officinarum is indigenous to Northern Italy, Western Balkans, Greece and Western Turkey, but can be cultivated in sheltered conditions in the United Kingdom. It is a perennial that produces a rosette of dark green leaves emerging from ground in spring, which are initially upright and then lie flat. It produces tubular bell shaped flowers in spring that are followed by spherical yellow fruit (Hawkes, 1972).

Mandrake has a long history of medicinal use, although superstition has played a large part in the uses to which it has been applied. The root is hallucinogenic and narcotic. In sufficient quantities, it induces a state of unconsciousness and was used as an anaesthetic for surgery in ancient times (Berry and Jackson, 1976). The special chemical properties of its root may have enhanced its reputation as highly desirable for its magical powers. The roots were so desirable that the rumours were spread abroad saying that when the root was pulled from the ground, a scream would be emitted that would kill any human who heard it. Thus it was that ingenious schemes were designed for a dog to be tied to the root and when called from a safe distance, pulled it up for its owner (Conway, 2016).

TROPANE ALKALOIDS

Atropine and scopolamine lead the tropane alkaloids uses in medicine. Both alkaloids belong to a class of natural chemicals and secondary plant metabolites that contain a tropane ring in their chemical structure. Both tropane alkaloids have pharmacological properties and can act as anticholinergics or stimulants. Atropine and scopolamine are very strong anticholinergic drugs used in medicine (Tian et al., 2015).

Atropine and scopolamine are among the most commonly used muscarinic antagonists in anesthesia. Scopolamine and atropine both easily penetrate the blood-brain barrier and these two alkaloids have long been known to produce undesirable side effects ranging from stupor (scopolamine) to delirium (atropine). Scopolamine and atropine may cause central nervous system toxicity. Its symptoms are delirium, restlessness, confusion, and impairment of mental capacities. Scopolamine is much more likely to produce sedation and amnesia than atropine, but scopolamine doesn't produce amnesia in all patients (Van Deuren and Missotten, 1979; Stone et al., 1988).

Tropane alkaloids (including calystegins) are present in many plant genera as *Anthocercis*, *Brugmansia*, *Datura*, *Hyoscyamus*, or *Solanaceae*, and today we have known for more than one hundreds of these alkaloids. However, atropine and scopolamine retain a privileged position, therefore this review article devoted primarily to these two natural substances and their synthetic derivatives with a similar pharmaceutical effect (Gryniewicz and Gadzikowska, 2008)

Atropine

Atropine (CAS Registry Number 51-55-8) is alkaloid which occurs naturally in a number of plants of the nightshade family including deadly nightshade, Jimson weed, and mandrake (Brust, 2004). It was first isolated in 1833 (Roberts, 1998). Atropine is used in medicine and is on the WHO Model List of Essential Medicines, the most important medications needed in a basic health system (WHO, 2014). Atropine is ester of bicyclic amine tropane-3 α -ol and tropic acid. The asymmetric α -carbon of tropic acid allows the formation of two stereoisomers. It is racemate (the mixture of S- and D-enantiomer). In plant sources only S-enantiomer (S-hyoscyamine, Fig. 2) is present but during the isolation, alkaloid is subjected to racemization. Atropine is used in medicine usually in the form of salt with sulfuric acid (atropine sulfate). Atropine is a widely used drug in the form of eyedrops, solutions for intravenous administration, and auto-injectors for nerve agent intoxication.




Figure 2. Chemical structure of hyoscyamine.

Atropine hypersensitivity

Atropine hypersensitivity is a rarely reported condition (Dundee and Mirakhur, 1978; Giala MM, Tzovairi-Tsakona, 1978; Economacos and Kanakis, 1981). However, in the military environment, such reactions are of significant concern given the threat of chemical warfare and the use of atropine as a nerve agent antidote. Upon deployment to regions where chemical attacks are a threat, each service member is issued three 2-mg intramuscular autoinjectors of atropine for self-treatment. Sensitivity testing revealed a significant reaction to <0.03 mg of intradermal atropine. This rarely reported reaction, in the military environment, poses a unique question regarding the suitability of deploying military members to areas where exposure to chemical warfare agents is possible (Hague and Derr, 2004).

Atropine in treatment of organophosphate nerve agent intoxication

Atropine is the drug of choice for treatment of organophosphate nerve agent and insecticide intoxication and has been used for this indication for several decades. Organophosphate nerve agents and insecticides are extremely toxic chemicals that exert their biological effects by inhibition of the enzyme acetylcholinesterase. The inhibited enzyme cannot hydrolyze mediator of cholinergic system – acetylcholine – resulting in the accumulation of this neurotransmitter in the muscarinic and nicotinic cholinergic synapses, and overstimulation of the cholinergic system (Geyer et al., 2009). Atropine is a competitive inhibitor of the muscarinic acetylcholine receptor. It blocks the effect of excess acetylcholine and protects the receptor from further stimulation. It has a minimal effect at nicotinic receptor site.

Exposure to organophosphorus (OP) chemicals has always been a potential poisoning threat to military personnel, however, this threat is now a growing concern for the civilian population today as well. Intoxication by OP chemicals can occur in instances of intentional and accidental release. OP chemicals are known inhibitors of acetylcholinesterase (AChE), resulting in increased acetylcholine levels in brain tissue and peripheral nerves that can lead to increased secretions, fasciculations, seizures, convulsions, respiratory distress, and death. Generally, OP chemical warfare nerve agents, such as sarin, soman, and VX, are much more toxic than bioactivated OP pesticides, such as paraoxon or chlorpyrifos-oxon, even though the mechanism of toxicosis via cholinergic hyperstimulation of parasympathetic nerves is the same.

Since the onset of toxic effects of OP is very quick, you must be submitted as soon as possible a suitable antidote. The primary components of the currently fielded therapies are (a) a competitive muscarinic receptor antagonist, atropine, to mitigate the excitotoxic effect at post-synaptic targets (Shutt and Bowes, 1979) and (b) an AChE oxime reactivator, to augment OP dissociation from and reactivation of inhibited AChE. The combination of these two therapeutic strategies aims to reduce the hyperstimulation of parasympathetic nerves that results from the over-accumulation of acetylcholine (Eyer, 2003). For use in emergency and pre-hospital settings, two-component autoinjector devices were developed (Bajgar, 2010).

During more than five decades, pyridinium oximes have been developed as therapeutic agents used in the medical treatment of poisoning with organophosphorus compounds (Jokanović and Prostran, 2009). Their mechanism of action is reactivation of AChE inhibited by OP agents. Presently, a combination of atropine, AChE reactivator such as one of the standard pyridinium oximes (pralidoxime, trimedoxime, obidoxime, HI-6) and diazepam has been used for the treatment of organophosphate poisoning in humans (Kuca et al., 2007).

Atropine in autoinjector as a source of children poisoning

It is unlikely that children are poisoned by atropine contained in an auto-injector, because this military material is or should be well guarded. Yet it happened. Automatic atropine injectors were distributed in Israel during the Persian Gulf Crisis as an antidote for chemical warfare agents. Over a period of 4 months, 268 cases of children poisoning after misuse of automatic atropine injectors were reported. The most common site of injection (75%) was the finger or palm. Doses were up to 17-fold higher than standard doses for age. In 116 children (48%), systemic effects of atropine were observed, and 20 (8%) had severe atropinization. Seizures and life-threatening arrhythmias were not reported, and there were no fatalities. Serum atropine levels (6.2 to 61.0 ng/mL) were much higher than those observed after administration of therapeutic doses (Amitai et al., 1992).

The article of Israel authors (Kozar et al., 2005) shows that the problem of atropine poisoning from automatic injectors in children still persists. Data collected from calls to the Israel Poison Information Center (IPIC) during a one-year period, and a cohort of children who were presented to pediatric emergency departments after unintentional injection of an automatic injector, summarized 142 patients. The median age was 8.5 years (range 1.25-18 years). The dose of atropine and TMB-4 was higher than the recommended dose for age in 22 (15.5%) cases. There were few side effects attributable to atropine: dilated pupils (26.7%), dryness of mucous membranes (24.6%), and tachycardia (22.5%). There were no side effects characteristic to oximes, and no specific medical intervention was required.

Scopolamine (hyoscine)

Scopolamine (CAS Registry Number 51-34-3) (1R,2R,4S,7S,9S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.0^{2,4}]non-7-yl ester of tropic acid. Scopolamine was first isolated from *Scopola carniolica* in 1881 and later on identified also in *Hyoscyamus niger* (Soban et al., 1989). Scopolamine is main tropane alkaloid in *Datura* sp. Like (-)-hyoscyamine also (-)-scopolamine easily forms racemic mixtures when being extracted (Kitagawa et al., 2000).

Scopolamine is an anti-muscarinic agent with central and peripheral actions. It crosses the blood-brain barrier, and its central action differs from that of atropine in that it depresses the cerebral cortex, especially the motor areas, and produces drowsiness and amnesia. It is effective in prevention and control of motion sickness and has also been given as an anti-emetic in the prophylactic treatment of other forms of nausea (Reynolds, 1996). Scopolamine was used in medicinal products for a specific range of indications. Particularly its derivative n-butylscopolamine bromide is regularly used in the treatment of abdominal pain associated with cramps induced by gastrointestinal spasms (Tytgat, 2007).

Scopolamine is used for premedication in anesthesia and for prevention of nausea and vomiting associated with motion sickness. Pharmacokinetics and pharmacodynamics of scopolamine depend on the dosage form. Scopolamine has a limited bioavailability if administered orally. Because of its short half-life in plasma and dose-dependent adverse effects (in particular hallucinations and the less serious reactions, eg, vertigo, dry mouth, drowsiness), the clinical use of scopolamine administered orally or parenterally is limited. To minimize the relatively high incidence of side effects, the transdermal dosage form has been developed (Wilkinson, 1987; Renner et al., 2005).

Scopolamine in the treatment of soman intoxication

Experiments in animal models suggest that scopolamine may be highly effective in the treatment of soman intoxications (Anderson et al., 1997; Philippens et al., 2005; Bonhange et al., 2009). Because soman intoxication is not treatable by conventional means antidotes, used in other OP intoxication (Bajgar, 1996), this finding is very significant (Koplovitz and Schulz, 2010). Scopolamine is also effective in the adjunctive treatment of poisoning by other OP agents (sarin) (Krivoy et al., 2004), and because it can be administered in aerosolized form, nasal drug delivery is a potential treatment option for mass casualty under field conditions (Che et al., 2011; Perkins et al., 2011).

Scopolamine-induced memory impairments

Memory impairment is a common symptom in patients with neurodegenerative disorders, and its suppression could be beneficial to improve the quality of life of those patients. Scopolamine as a nonselective centrally active muscarinic antagonist has been frequently used to model aspects of the memory impairment of normal aging and of dementia (Molchan et al., 1990). Scopolamine is used as a memory impairment model to produce memory and cognitive dysfunctions (Jamialahmadi et al., 2013; Souza et al., 2013; Hosseini et al., 2015; Karimi et al., 2015; Mohammadpour et al., 2015).

ATROPINE-LIKE CHEMICAL WARFARE AGENTS

Atropine-like drugs are pharmacologically classified as muscarinic receptor antagonists, which compete with acetylcholine for a common binding site on the muscarinic receptor. This binding prevents acetylcholine from binding to muscarinic cholinergic receptors at neuroeffector sites on smooth muscle, heart muscle, glands, peripheral ganglia and at centrally active antagonists mainly in the CNS (McDonough and Shih, 2007), where they act as psychotomimetics (Fusek et al., 2015).

Psychotomimetic Chemical Weapons

In the 1950s, a number of anticholinergic drugs with psychotomimetic effect, were investigated for potential industrial and military use. The research of these substances was attributed to the increasing interest of the US military in exploring chemical warfare agents which were non-lethal but incapacitating (Streda and Patocka, 2014).

Non-lethal weapons are weapons which are explicitly designed and developed to incapacitate or repel personnel, with a low probability of fatality or injury (NATO, 1999). Psychotomimetic chemical weapons are acting on the mind. These substances administered in low doses (<10 mg) cause conditions similar to psychotic disorders or other symptoms emanating from the CNS, for example loss of feeling, paralysis, rigidity, etc. These effects are transitory and cause inability to make decisions and incapacitation. Investigations in the USA have shown that an important group of substances with a psychotomimetic effect is the group of esters of glycolic acid (glycolates). Particular interest was paid to 3-quinuclidinyl benzilate, code-named Agent BZ. The effects of this group of substances are similar to those caused by atropine. BZ causes poisoning at doses of 0.5-5 mg. Peripheral symptoms such as distended pupils, deteriorated short-distance vision, dry mouth and palpitations occur after about 30 minutes (Misik, 2013).

Agent BZ

Agent BZ (CAS Registry Number 651-06-2, Agent Buzz, EA 2277, Ro 2-3308, QB, QNB, 3-quinuclidinyl benzilate, Fig. 3) is white, odorless crystalline solid which is absorbed mainly via oral route, or respiratory system when dispersed as aerosol. BZ was first synthesized by Hoffman-LaRoche as a possible ulcer remedy and originally as studies for the therapy of gastrointestinal diseases (Ketchum, 2006). But even in small doses, it produces unpleasant side effects (confusion a hallucination). BZ easily crosses the blood-brain barrier and interacts with all subtypes of muscarinic receptors responsible for various central effects. Onset of anti-cholinergic signs is rapid, observed immediately after subcutaneous injection of high doses or several min after low doses (Liu et al., 1984).




Figure 3. Chemical structure of Agent BZ (3-quinuclidinyl benzilate).

BZ is a non-selective, competitive agonist of cholinergic receptor. Similarly as atropine or scopolamine, BZ competes with neuromediator acetylcholine at muscarinic receptors in both, central and peripheral sites. A serious effect of poisoning with BZ, as also with other atropine-like substances, is increased body temperature. Central effects are connected with psychotomimetic incapacitating signs such as e.g. confusion, disorientation or delusions, and may result into unpredictable and irrational behaviour (Sidell, 1982). Therefore, BZ was withdrawn from commercial studies and turned over to the US army as a possible candidate for incapacitating agents (Hoenig, 2007). US Army begins experimenting with BZ as an incapacitant in 1958 (Lee and Shlain, 1985).

Action of BZ is expected to be long-lasting with significant behavioral effects within 24 hours in rats. A noticeable, but non-significant, behavioral effect was observed even 7 days after administration (Kunesova et al., 2008). The mean duration of incapacitation is considered to be about 70 hours in a man and may remain 1-3 weeks after the poisoning (Fusek et al., 2015). Since the effect of glycolates was found to be difficult to predict, interest in continued research into this type of substance gradually decreased.

Biphasic effect of BZ observed in animals (Liu et al., 1984) has the same course as in humans. The first stage, which lasts up to 4 hours in a man, is characterized by hyperactivity, muscle spasms, feelings of unrest and discomfort. The second stage, lasting up to 4 to 12 hours is connected with sedation and inactivity. Complex hallucinations continue 24 to 48 hours post exposure. Low effective dose (ED) expected to induce incapacitation in a man is 0.006 - 0.01mg.kg⁻¹ (i.m.) (Fusek et al., 2015).

Analogues of BZ

A number of analogues of BZ have been synthesized and their affinities to muscarinic receptor from rat or dog ventricular muscle were measured (Rzeszotarski et al., 1982). Their *in vitro* competition studies show that the affinities lie within a 270-fold range, from the highest affinity compound, 3-quinuclidinyl α -hydroxy- α -cyclopentylphenyl acetate, to the lowest affinity compound, 3-quinuclidinyl α -hydroxy- α -2-propargylphenyl acetate.

N-Methyl-3-piperidyl benzilate (CAS Registry Number 3321-80-0, JB-336, Fig. 4) is an anticholinergic drug related to the chemical warfare agent 3-quinuclidinyl benzilate (Rump et al., 1967). It is less potent and shorter acting than BZ and LSD (Bajgar et al., 1971; Kabes et al., 1971). Radiolabelled versions of this drug are used in scientific research to map the distribution of muscarinic acetylcholine receptors in the brain (Takahashi et al., 1999).

N-Ethyl-3-piperidyl benzilate (CAS Registry Number 3567-12-2, JB-318, Fig. 4) is an anticholinergic drug related to the chemical warfare agent 3-Quinuclidinyl benzilate (Ostfeld et al., 1959). This analogue of BZ is less potent and shorter acting than BZ, but like BZ its effects on the central nervous system predominate over peripheral effects (Lebovits et al., 1960; Ostfeld, 1961). It produces deliriant and hallucinogenic effects similar to those of plants such as datura and may be used recreationally at low doses; however, unpleasant side effects such as dysphoria, nausea and vomiting, dizziness and extreme dry mouth tend to make abuse of drugs of this kind uncommon (Menozzi and Scarlato, 1964; Nishiyama et al., 2001). Radiolabelled versions of this drug are used in scientific research to map the distribution of muscarinic acetylcholine receptors in the brain (Nishiyama et al., 2001). Both the N-methyl and N-ethyl analogues of 3-piperidyl benzilate are, however, Schedule I controlled drugs.

Ditran (CAS Registry Number 8015-54-1, JB-329, Fig. 4) is an anticholinergic drug mixture, related to the chemical warfare agent BZ (Gershon and Olariu, 1960). Ditran is an anticholinergic drug with hallucinogenic properties causing intense mental confusion. It is composed of a mixture of 70% 1-ethyl-2-pyrrolidinylmethyl- α -phenylcyclopentyl glycolate and 30% 1-ethyl-3-piperidyl- α -phenylcyclopentyl glycolate (Hollister et al., 1960). These compounds are structural isomers and have very similar pharmacological properties. The piperidine compound is the more potent of the two and the reason the mixture was used was because of ease of manufacture, however it is also possible to make the piperidine compound in its pure form, so there were ultimately two forms of Ditran used in research, the original 70/30 mix, and "Ditran-B", the pure piperidine compound (Burchard, 1962; Davis et al., 1964). Ditran was developed during chemical weapons research in an attempt to produce non-lethal incapacitating agents, similar to BZ itself. The ditran mixture is more potent as an anticholinergic than the piperidyl benzilate drugs such as N-methyl-3-piperidyl benzilate, but is less potent than BZ (Baryshnikov et al., 1968).




Figure 4. Chemical structures of JB-336, JB-318 and JB-329.

CONCLUSIONS

Atropine and similar substances will still have its place in the general medicine and they are also in military medicine. Anticholinergics are also playing an increasingly important place in psychiatry. Problematic issue remains the possible misuse of centrally acting anticholinergics as psychologically debilitating substances. These could be exploited in war and in terrorist activities.

DISCLOSURE STATEMENT

The authors proclaim that they have no competing interests.

ACKNOWLEDGEMENT

This work was supported by the long-term organization development plan (University Hospital, Hradec Kralove, Czech Republic).

ABBREVIATIONS

- HI-6 (1-[[[4-(aminocarbonyl)pyridinio]methoxymethyl]-2-[(hydroxyimino)methyl]-pyridinium dichloride)
- LSD Lysergyl diethylamide, (6aR,9R)- N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]chinolin-9-karboxamid
- TMB-4 Trimedoxime, 1,3-bis-(4-hydroxyiminomethylpyridinium)propane dibromide
- VX Ethyl ({2-[bis(propan-2-yl)amino]ethyl}sulfanyl)(methyl)phosphinate

REFERENCES

1. Abdelouahab B, Nadia M, Nabila K. Toxicity studies of alkaloids of seeds of *Datura stramonium* and synthesis alkaloids in male rats. *J Med Plant Res.* **2011**, 5(15), 3421-3431.
2. Amitai Y, Almog S, Singer R, Hammer R, Bentur Y, Danon YL. Atropine poisoning in children during the Persian Gulf crisis. A national survey in Israel. *JAMA.* **1992**, 268(5), 630-632.
3. Anderson DR, Harris LW, Chang FC, Baze WB, Capacio BR, Byers SL, Lennox WJ. Antagonism of soman-induced convulsions by midazolam, diazepam and scopolamine. *Drug Chem Toxicol.* **1997**, 20(3), 115-131.
4. Aparna K, Joshi AJ, Vyas M. Phyto-chemical and pharmacological profiles of *Hyoscyamus niger* Linn (Parasika Yavani) – a review. *Pharma Sci Monitor.* **2015**, 6(1), 153-159.
5. Bajgar J, Patočka J, Zizkovský V. The inhibition of human brain acetylcholinesterase by LSD-25 and JB-336 in vitro. *Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl.* **1971**, 14(4), 417-423.
6. Bajgar J. Present views on toxodynamics of soman poisoning. *Acta Medica (Hradec Kralove).* **1996**, 39(3), 101-105.
7. Bajgar J. Optimal choice of acetylcholinesterase reactivators for antidotal treatment of nerve agent intoxication. *Acta Medica (Hradec Kralove).* **2010**, 53(4), 207-211.
8. Baryshnikov II, Blagovidoca LL, Milshtein GI. [To the pharmacology of ditran]. *Farmakol Toksikol.* **1968**, 31(4), 434-436. Russian.
9. Begum S, Saxena B, Goyal M, Ranjan R, Joshi VB, Rao CV, Krishnamurthy S, Sahai, M. Study of anti-inflammatory, analgesic and antipyretic activities of seeds of *Hyoscyamus niger* and isolation of a new coumarinolignan. *Fitoterapia*, **2010**, 81(3), 178-184.
10. Berry MI, Jackson BP. European mandrake (*Mandragora officinarum* and *M. autumnalis*). *Planta Medica.* **1976**, 30(7), 281-290.

11. Bonhage MR, Chilcoat CD, Li Q, Melendez V, Flournoy WS. Evaluation of two scopolamine and physostigmine pretreatment regimens against nerve agent poisoning in the dog. *J Vet Pharmacol Ther.* **2009**, 32(2), 146-153.
12. Brighetti A. [From belladonna to atropine. (Medical historical note)]. *Policlinico Prat.* **1966**, 73(35), 1171-1174. Italian.
13. Brust JCM. Neurological aspects of substance abuse (2 ed.). Philadelphia: Elsevier. **2004**, p. 310. ISBN 9780750673136.
14. Buess H. History of Atropa belladonna as a drug. *Gesnerus.* **1953**, 10(1-2), 37-52.
15. Burchard JM. [On the structure of delusional syndromes. (Impulse and object relationship in Ditrans studies)]. *Fortschr Neurol Psychiatr Grenzgeb.* **1962**, 30, 602-613. German.
16. Che MM, Chanda S, Song J, Doctor BP, Rezk PE, Sabnekar P, Perkins MW, Sciuto AM, Nambiar MP. Aerosolized scopolamine protects against microinstillation inhalation toxicity to sarin in guinea pigs. *Toxicol Mech Methods.* **2011**, 21(6), 463-472.
17. Conway D. Magic: An Occult Primer. The Witches' Almanac, Ltd, Newport, USA **2016**. ISBN 978-1-904658-72-6.
18. Davis HK, Ford HF, Tupin JP, Colvin A. Clinical evaluation of JB-329 (DITRAN). *Dis Nerv Syst.* **1964**, 25, 179-183.
19. Dundee JW, Mirakhr RK. Hypersensitivity to atropine. *Br J Anaesth.* **1978**, 50(8), 866.
20. Economacos G, Kanakis J. [A case of hypersensitivity to atropine]. *Anesth Analg (Paris).* **1981**, 38(11-12), 748. French.
21. Eyer P. The role of oximes in the management of organophosphorus pesticide poisoning. *Toxicol Rev.* **2003**, 22(3), 165-190.
22. Fowler CJ. Plant sources of antimuscarinics. *BJU Intern.* **2015**. 115(S6): 4-7.
23. Friedman M, Levin CE. Composition of jimson weed (*Datura stramonium*) seeds. *Agr Food Chem.* **1989**, 37(4), 998-1005.
24. Fusek J, Bajgar J, Kassa J, Kuca K, Jun D. Psychotomimetic Agent BZ (3-Quinuclidinyl Benzilate). In Gupta RC (Ed.) Handbook of Toxicology of Chemical Warfare Agents. Second Ed. Elsevier. **2015**. ISBN 978-0-12-800159-2
25. Gaire BP, Subedi L. A review on the pharmacological and toxicological aspects of *Datura stramonium* L. *J Integrative Med.* **2013**, 11(2), 73-79.
26. Gershon S, Olariu J. JB 329 degrees - a new psychotomimetic, its antagonism by tetrahydroaminacrin and its comparison with LSD, mescaline and sernyl. *J Neuropsychiatr.* **1960**, 1, 283-292.
27. Geyer BC, Evron T, Soreq H, Mor TS. Organophosphate intoxication: Molecular consequences, mechanisms and solutions. In: Gupta RC (Ed.) Handbook of Toxicology of Chemical Warfare Agents. Elsevier. **2009**, pp. 691-717.
28. Giala MM, Tzovairi-Tsakona H. Hypersensitivity to atropine. *Br J Anaesth.* **1978**, 50(3), 305.
29. Grynkiewicz G, Gadzikowska M. Tropane alkaloids as medicinally useful natural products and their synthetic derivatives as new drugs. *Pharmacol Rep.* **2008**, 60(4), 439-463.
30. Hague JD, Derr JJ. Military implications of atropine hypersensitivity. *Mil Med.* **2004**, 169(5), 389-391.
31. Hawkes JG. Mandragora. In Tutin TG, Heywood H, Burges NA, Valentine DH, Walters SM, Webb DA. Flora Europaea, Volume 3: Diapensiaceae to Myoporaceae. Cambridge University Press. **1972**, pp. 199-200. ISBN 978-0-521-08489-5.
32. Hoenig SL. Incapacitating agents: Agent-BZ. In Compendium of Chemical Warfare Agents. New York: Springer, **2007**, 73-76.
33. Hollister LE, Prusmack JJ, Paulsen A, Rosenquist N. Comparison of three psychotropic drugs (psilocybin, JB-329, and IT-290) in volunteer subjects. *J Nerv Ment Dis.* **1960**, 131, 428-434.
34. Hosseini M, Mohammadpour T, Karami R, Rajaei Z, Reza Sadeghnia H, Soukhtanloo M. Effects of the hydro-alcoholic extract of *Nigella sativa* on scopolamine-induced spatial memory impairment in rats and its possible mechanism. *Chin J Integr Med.* **2015**, 21(6), 438-444.
35. Jamialahmadi K, Sadeghnia HR, Mohammadi G, Kazemabad AM, Hosseini M. Glucosamine alleviates scopolamine induced spatial learning and memory deficits in rats. *Pathophysiology.* **2013**, 20(4), 263-267.
36. Jokanović M, Prostran M. Pyridinium oximes as cholinesterase reactivators. Structure-activity relationship and efficacy in the treatment of poisoning with organophosphorus compounds. *Curr Med Chem.* **2009**, 16(17), 2177-2188.
37. Kabes J, Fink Z, Fusek J, Vachek J. Central anticholinergic activity of JB 336. *Act Nerv Super (Praha).* **1971**, 13(3), 193-194.

38. Karimi S, Hejazian SH, Alikhani V, Hosseini M. The effects of tamoxifen on spatial and nonspatial learning and memory impairments induced by scopolamine and the brain tissues oxidative damage in ovariectomized rats. *Adv Biomed Res.* **2015**, 4, 196.
39. Ketchum JS. Chemical warfare: Secrets almost forgotten. James S. Ketchum, **2006**. pp. 360. ISBN 9-781-42430080-8
40. Kitagawa I, Ishizu T, Ohashi K, Shibuya H. [Chirality of natural products: hyoscyamine and scopolamine]. *Yakugaku Zasshi.* **2000**, 120(10), 1017-1023. Japanese.
41. Koplovitz I, Schulz S. Perspectives on the use of scopolamine as an adjunct treatment to enhance survival following organophosphorus nerve agent poisoning. *Mil Med.* **2010**, 175(11), 878-882.
42. Kozer E, Mordel A, Haim SB, Bulkowstein M, Berkovitch M, Bentur Y. Pediatric poisoning from trimefoxime (TMB4) and atropine automatic injectors. *J Pediatr.* **2005**, 146(1), 41-44.
43. Krivoy A, Layish I, Rotman E, Yehezkeli Y. Treatment of sarin exposure. *JAMA.* **2004**, 291(2), 181.
44. Kuca K, Jun D, Bajgar J. Currently used cholinesterase reactivators against nerve agent intoxication: comparison of their effectivity in vitro. *Drug Chem Toxicol.* **2007**, 30(1), 31-40.
45. Kunesova G, Hlavacek J, Patocka J, Evangelou A, Zikos C, Benaki D, Paravatou- Petsotas M, Pelecanou M, Livanou E, Slaninova J. The multiple T-maze in vivo testing of the neuroprotective effect of humanin analogues. *Peptides.* **2008**, 29(11), 1982-1987.
46. Lebovits BZ, Visotsky HM, Ostfeld AM. LSD and JB 318: a comparison of two hallucinogens. I. An exploratory study. *AMA Arch Gen Psychiatry.* **1960**, 2, 390-407.
47. Lee MA, Shlain B. Acid Dreams. The CIA, LSD and the Sixties Rebellion. Grove Press, **1985**, pp. 343. ISBN 0-802-13063-3
48. Lee MR. Solanaceae. IV. Atropa belladonna, Deadly nightshade. *J R Coll Edinb.* **2007**, 37(1), 77-84.
49. Lee MR. The snowdrop (*Galanthus nivalis*). From Odysseus to Alzheimer. *Proc R Coll Phys Edinb.* **1999**, 29(4), 349-352.
50. Le Strange R. A History of Herbal Plants. London: Angus and Robertson, London **1977**. ISBN 978-0-668-04247-5
51. Liu WF, Hu NW, Beaton JM. Biphasic effects of 3-quinuclidinyl benzilate on spontaneous motor activity in mice. *Psychopharmacology.* **1984**, 84(4): 486-488.
52. McDonough JH, Shih TM. Atropine and Other Anticholinergic Drugs in: Marrs TT, Maynard RL, Sidell F. (Eds.) Chemical Warfare Agents: Toxicology and Treatment. Wiley Publ. **2007**. ISBN 978-0-470-01359-5
53. Menozzi C, Scarlato G. [JB-318 and atropine: Comparative study of the effects induced in normal subjects]. *Arch Psicol Neurol Psichiatr.* **1964**, 25, 205-233. Italian
54. Misik J. Military incapacitating agent BZ (3-quinuclidinyl bezilate) - past, present and future. *Mil Med Sci Lett.* **2013**, 82(3), 115-119.
55. Mohammadpour T, Hosseini M, Naderi A, Karami R, Sadeghnia HR, Soukhtanloo M, et al. Protection against brain tissues oxidative damage as a possible mechanism for the beneficial effects of Rosa damascena hydroalcoholic extract on scopolamine induced memory impairment in rats. *Nutr Neurosci.* **2015**, 18(7), 329-336.
56. Molchan SE, Mellow AM, Lawlor BA, Weingartner HJ, Cohen RM, Cohen NR, Sunderland T. TRH attenuates scopolamine-induced memory impairment in humans. *Psychopharmacology.* **1990**, 100(1), 84-89.
57. NATO. NATO Policy for Non-Lethal Weapons. NATO Press Statement, 13 October **1999**.
58. Nishiyama S, Tsukada H, Sato K, Kakiuchi T, Ohba H, Harada N, Takahashi K. Evaluation of PET ligands (+)N-[11C]ethyl-3-piperidyl benzilate and (+)N-[11C]propyl-3-piperidyl benzilate for muscarinic cholinergic receptors: a PET study with microdialysis in comparison with (+)N-[11C]methyl-3-piperidyl benzilate in the conscious monkey brain. *Synapse* **2001**, 40(3), 159-169.
59. Ostfeld AM. Effects of LSD 25 and JB 318 on tests of visual and perceptual functions in man. *Fed Proc.* **1961**, 20, 876-884.
60. Ostfeld AM, Visotsky H, Abood L, Lebovitz BZ. Studies with a new hallucinogen; some dosage-response data for JB 318. *AMA Arch Neurol Psychiatry.* **1959**, 81(2), 256-263.
61. Parveen A, Vijula K, Avinash KV, Ravishankar M, Leeladhar DV. Medicinal values of Datura: A synoptic review. *Int J Green Pharm.* **2016**, 10(2), 77-81.
62. Perkins MW, Pierre Z, Rezk P, Song J, Oguntayo S, Morthole V, Sciuto AM, Doctor BP, Nambiar MP. Protective effects of aerosolized scopolamine against soman-induced acute respiratory toxicity in guinea pigs. *Int J Toxicol.* **2011**, 30(6), 639-649.

63. Philippens IH, Joosen MJ, Vanwersch RA. Stress adversely affects efficacy of physostigmine-scopolamine pretreatment against soman in guinea pigs. *Pharmacol Biochem Behav.* **2005**, 82(1), 125-132.
64. Ramoutsaki IA, Askitopoulou H, Konsolaki, E. Pain relief and sedation in Roman Byzantine texts: Mandragoras officinarum, Hyoscyamos niger and Atropa belladonna. In *International Congress Series* (Vol. 1242, pp. 43-50). Elsevier, **2002**.
65. Renner UD, Oertel R, Kirch W. Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. *Ther Drug Monit.* **2005**, 27(5), 655-665.
66. Reynolds JEF (Ed.) Martindale: The Extra Pharmacopoeia. 31 edn. London, The Pharmaceutical Press, **1996**, 499-500.
67. Roberts MF. (Ed.). Alkaloids: biochemistry, ecology, and medicinal applications. Springer Science & Business Media, **1998**, pp 482.
68. Rump S, Faff J, Siek S. [Effects of N-methyl-3-hydroxypiperine benzilate (JB 336) on some conditioning responses of the rat]. *Acta Physiol Pol.* **1967**, 18(1), 89-95. Polish
69. Rzeszutarski WJ, Gibson RE, Eckelman WC, Simms DA, Jagoda EM, Ferreira NL, Reba RC. Analogues of 3-quinuclidinyl benzilate. *J Med Chem.* **1982**, 25(9), 1103-1106.
70. Shutt LE, Bowes JB. Atropine and hyoscine. *Anaesthesia.* **1979**, 34(5): 476-490.
71. Sidell FR. Possible long-term health effects of short-term exposure to chemical agents. Vol. 1. Anticholinesterases and anticholinergics. In: Panel on anticholinesterase chemicals, panel on anticholinergic chemicals, committee on toxicology, board on toxicology and environmental health hazards, eds. National Academy Press, Washington DC. **1982**, p. 284.
72. Soban D, Ruprecht J, Keys TE, Schneck HJ. [The history of scopolamine—with special reference to its use in anesthesia]. *Anaesthesiol Reanim.* **1989**, 14(1), 43-54. German.
73. Souza AC, Bruning CA, Acker CI, Neto JS, Nogueira CW. 2-Phenylethynyl-butyltellurium enhances learning and memory impaired by scopolamine in mice. *Behav Pharmacol.* **2013**, 24(4), 249–254.
74. Stone WS, Croul CE, Gold PE. Attenuation of scopolamine-induced amnesia in mice. *Psychopharmacology (Berl).* **1988**, 96(3), 417-420.
75. Streda L, Patocka J. Incapacitating chemicals – Risk to the purpose and objectives of the Chemical Weapons Convention? *Kontakt* **2014**, 16, e57-e63.
76. Takahashi K, Murakami M, Miura S, Iida H, Kanno I, Uemura K. Synthesis and autoradiographic localization of muscarinic cholinergic antagonist (+)N-[¹¹C]methyl-3-piperidyl benzilate as a potent radioligand for positron emission tomography. *Applied Radiation and Isotopes.* **1999**, 50(3), 521–525.
77. Tian F, Li C, Wang X, Ren S, Li N, Liu Q, Zhou S, Lu Y, Zhao D, Chen X. Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats. *Eur J Drug Metab Pharmacokinet.* **2015**, 40(3), 245-253.
78. Tytgat GN. Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. *Drugs.* **2007**, 67(9), 1343-1357.
79. Urich RW, Bowerman DL, Levisky JA, Pflug JL. Datura stramonium: a fatal poisoning. *J Forensic Sci.* **1982**, 27(4), 948-954.
80. Van Deuren H, Missotten L. Atropine intoxication and the acute delirium of the elderly blind patient. *Bull Soc Belge Ophtalmol.* **1979**, 186, 27-29.
81. WHO. Model List of Essential Medicines. World Health Organization. October **2013**. p. 6. Retrieved 22 April 2014.
82. Wilkinson JA. Side effects of transdermal scopolamine. *J Emerg Med.* **1987**, 5(5), 389-392.
83. Ylinen M, Naaranlahti T, Lapinjoki S, Huhtikangas A, Salonen ML, Simola LK, Lounasmaa M. Tropane alkaloids from *Atropa belladonna*; Part I. Capillary gas chromatographic analysis. *Planta Medica.* **1986**, 52(02), 85-87.